Array BioPharma, Inc.

Array BioPharma, Inc. is a biopharmaceutical company based in the US that focuses on developing innovative therapies for cancer and other serious diseases. Array BioPharma, Inc. specializes in biopharmaceutical development, headquartered in Boulder, Colorado, US.

The company was founded in 1998 and has been involved in 9 deals, with its most recent deal occurring on November 17, 2000, when it completed an IPO. The CEO team includes Robert Conway, Theperemedy Carruth, and Tracy Knauf. The company raised a total of USD 8. 50 mn in its latest funding round, which was backed by Amgen Ventures.

Array BioPharma, Inc. develops innovative therapies aimed at treating various health challenges, particularly in oncology. Their product offerings include advanced cancer treatments designed to target and manage disease progression, ultimately aiming to improve patient outcomes. The company serves healthcare providers and patients in markets including North America, Europe, and Asia-Pacific, ensuring the availability of its treatments.

In the year 2018, Array BioPharma, Inc. reported revenue of USD 173. 77 mn, with an EBITDA of USD -127. 69 mn.

The company's revenue is generated primarily through the sales of its biopharmaceutical products, ensuring broad access via partnerships with healthcare providers and institutions. Looking ahead, Array BioPharma, Inc. plans to expand its offerings with new product launches in oncology. The company is also targeting growth in new geographic markets, specifically in Europe and Asia, aiming to establish a presence by 2025.

The recent funding of USD 8. 50 mn will be utilized to support these initiatives, enhancing their research and development capabilities and facilitating market entry strategies.